- Q4 2023 Oncternal Therapeutics Inc Earnings Call TranscriptMar 07, 2024$9.25 (-3.14%)Earnings
- Q3 2023 Oncternal Therapeutics Inc Earnings Call TranscriptNov 09, 2023$6 (-9.07%)Earnings
- Q2 2023 Oncternal Therapeutics Inc Earnings Call TranscriptAug 10, 2023$6.78 (-6.71%)Earnings
- Oncternal Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Oncternal Therapeutics Inc Earnings Call TranscriptMay 04, 2023$6.32 (-3.60%)Earnings
- Oncternal Therapeutics Inc To Discuss Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 TranscriptApr 03, 2023
- Q4 2022 Oncternal Therapeutics Inc Earnings Call TranscriptMar 09, 2023$17.72 (-0.56%)Earnings
- Q3 2022 Oncternal Therapeutics Inc Earnings Call TranscriptNov 03, 2022$20 (-1.96%)Earnings
- Q2 2022 Oncternal Therapeutics Inc Earnings Call TranscriptAug 09, 2022$22.2 (-4.31%)Earnings
- Q1 2022 Oncternal Therapeutics Inc Earnings Call TranscriptMay 05, 2022$22 (+1.85%)Earnings
- Q4 2021 Oncternal Therapeutics Inc Earnings Call TranscriptMar 10, 2022$33.6 (-2.89%)Earnings
- Oncternal Therapeutics Inc Host Key Opinion Leader Webinar TranscriptJan 25, 2022
- Oncternal Therapeutics Inc to Announce Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab Call TranscriptJan 04, 2022
- Q3 2021 Oncternal Therapeutics Inc Earnings Call TranscriptNov 04, 2021$81.4 (+6.54%)Earnings
- Q2 2021 Oncternal Therapeutics Inc Earnings Call TranscriptAug 05, 2021$77.6 (+3.47%)Earnings
- Q1 2021 Oncternal Therapeutics Inc Earnings Call TranscriptMay 06, 2021$109 (-9.02%)Earnings
- Q4 2020 Oncternal Therapeutics Inc Earnings Call TranscriptMar 11, 2021$127.4 (+10.40%)Earnings
- Q2 2020 Oncternal Therapeutics Inc Earnings Call TranscriptAug 06, 2020$57.4 (-2.71%)Earnings
- Oncternal Therapeutics Inc Key Opinion Leader (KOL) Webinar on Cirmtuzumab for Treating Patients with Mantle Cell TranscriptJul 29, 2020
- Q1 2020 Oncternal Therapeutics Inc Earnings Call TranscriptMay 07, 2020$50 (-5.87%)Earnings
- Q4 2019 Oncternal Therapeutics Inc Earnings Call TranscriptMar 16, 2020$66.6 (+3.26%)Earnings
- Q3 2019 Oncternal Therapeutics Inc Earnings Call TranscriptNov 07, 2019$115.6 (-3.99%)Earnings
- Q2 2019 Oncternal Therapeutics Inc Earnings Call TranscriptAug 08, 2019$88.6 (+3.75%)Earnings
- GTx, Inc and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Call TranscriptMar 07, 2019
Oncternal Therapeutics Inc Host Key Opinion Leader Webinar Transcript
Good afternoon, and welcome to the Oncternal Therapeutics KOL webinar on hematological malignancies and prostate cancer. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Oncternal website following the conclusion of the event.
I'd now like to turn the call over to your host, Dr. Mr. Jim Breitmeyer, President and Chief Executive Officer of Oncternal. Please go ahead, Jim.
Thank you, Pauline, and it's my pleasure to welcome you all to Oncternal's R&D day and our focus on hematologic malignancies and prostate cancer.
So if I can have the next slide. This is the agenda. The first half of the present presentation will focus on Heme Malignancies with our speaker, Dr. Michael Wang from MD Anderson and then Oncternal management will provide an update of the zilovertamab antibody program and the ROR1 cell therapy program. A Q&A will follow that section.
Then in the second half, we will be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)